No evidence of occult HBV infection in population born after mass vaccination

A letter to the editor to this article was published on 20 July 2020

Summary

Despite access to efficient hepatitis B virus (HBV) vaccine and universal immunization schedules, HBV infection remains a global health concern. HBV infection has decreased by this program. Nevertheless, breakthrough infections occur due to generation of occult HBV infection (OBI) and surface gene mutants in the immunized population. We aimed to determine the presence of OBI in a population born after initiation of nationwide HBV vaccination in Tehran, Iran. A HBV mass vaccination schedule was launched in Iran in 1993. For this study, we enrolled 1120 cases younger than 24 years. ELISA was applied to evaluate the presence of HBsAg, anti-HBs and anti-HBc. HBV-DNA presence was determined in all HBsAg-negative cases using nested polymerase chain reaction. The prevalence of HBsAg, anti-HBc and anti-HBs was 0.1, 0.54 and 39.9% respectively. Out of 6 anti-HBc-positive individuals, 4 cases also had anti-HBs. One case revealed HBsAg co-existence and the other one showed isolated anti-HBc. HBV-DNA was not detected in HBsAg-negative specimens. A very low prevalence of HBsAg and isolated anti-HBc was observed and no occult HBV infection was detected. It seems that evasion mutants are not a potential threat for HBV universal immunization efficacy in the vaccinated population.

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. 1.

    El-Seraq HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27. https://doi.org/10.1056/NEJMra1001683.

    Article  Google Scholar 

  2. 2.

    van der Sande MA, Waight PA, Mendy M, Zaman S, Kaye S, Sam O et al. Long-term protection against HBV chronic carriage of Gambian adolescents vaccinated in infancy and immune response in HBV booster trial in adolescence. PLoS One. 2007;2(8):e753. https://doi.org/10.1371/journal.pone.0000753.

    Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Chang MH. Breakthrough HBV infection in vaccinated children in Taiwan. Surveillance for HBV mutants. Antivir Ther. 2010;15:463–9. https://doi.org/10.3851/IMP1555.

    Article  PubMed  Google Scholar 

  4. 4.

    McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow up. Ann Intern Med. 2005;142:333–41. https://doi.org/10.7326/0003-4819-142-5-200503010-00008.

    Article  PubMed  Google Scholar 

  5. 5.

    Ngui SL, Andrews NJ, Underhill GS, Heptonstall J, Teo CG. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis. 1998;27:100–6.

    CAS  Article  Google Scholar 

  6. 6.

    Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71(2):397–408.

    Article  Google Scholar 

  7. 7.

    Aghakhani A, Mohraz M, Aghasadeghi MR, Banifazl M, Vahabpour R, et al. Occult hepatitis B virus infection and S gene escape mutants in HIV-infected patients after hepatitis B virus vaccination. Int J STD Aids. 2016;27(11):967–72. https://doi.org/10.1177/0956462415602419.

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Aghakhani A, Banifazl M, Kalantar E, Eslamifar A, Ahmadi F, Razeghi E, et al. Occult hepatitis B virus infection in hemodialysis patients with isolated hepatitis B core antibody. A multicenter study. Ther Apher Dial. 2010;14(3):349–53. https://doi.org/10.1111/j.1744-9987.2009.00798.x.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Azadmanesh K, Mohraz M, Aghakhani A, Edalat R, Jam S, Eslamifar A et al. Occult hepatitis B virus infection in HIV-infected patients with isolated hepatitis B core antibody. Intervirology. 2008;51(4):270–4. https://doi.org/10.1159/000160217.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology. 2017;65:1451–61.

    CAS  Article  Google Scholar 

  11. 11.

    Hsu HY, Chang MH, Ni YH, Chiang CL, Wu JF, Chen HL. Universal infant immunization and occult hepatitis B virus infection in children and adolescents: a population-based study. Hepatology. 2015;61:1183–91.

    CAS  Article  Google Scholar 

  12. 12.

    Ramezani A, Aghasadeghi MR, Ahmadi F, Razeghi E, Eslamifar A, Banifazl M, et al. Isolated anti-hbc and occult HBV infection in dialysis patients. Nephrourol Mon. 2014;7(1):e22674. https://doi.org/10.5812/numonthly.22674.

    Article  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, Ciancio A, et al. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int. 2015;35:2311–7.

    CAS  Article  Google Scholar 

  14. 14.

    Lusida M, Juniastuti, Yano Y. Current hepatitis B virus infection situation in Indonesia and its genetic diversity. World J Gastroenterol. 2016;22(32):7264–74. https://doi.org/10.3748/wjg.v22.i32.7264.

    Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Ponde RA. Molecular mechanisms underlying HBsAg negativity in occult HBV infection. Eur J Clin Microbiol Infect Dis. 2015;34:1709–31.

    CAS  Article  Google Scholar 

  16. 16.

    Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479–86. https://doi.org/10.1016/S1473-3099(02)00345-6.

    Article  PubMed  Google Scholar 

  17. 17.

    Kim H, Kim BJ. Association of preS/S mutations with occult hepatitis B virus (HBV) infection in South Korea. Transmission potential of distinct occult HBV variants. Int J Mol Sci. 2015;16(6):13595–609. https://doi.org/10.3390/ijms160613595.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Teo CG, Locarnini S. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antivir Ther. 2010;15:445–9.

    Article  Google Scholar 

  19. 19.

    Huang C‑H, Yuan Q, Chen PJ, Zhang YL, Chen CR, Zheng QB, et al. Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors. J Hepatol. 2012;57(4):720–9.

    CAS  Article  Google Scholar 

  20. 20.

    World Health Organization. Expanded programme on immunization. Global advisory group. Wkly Epidemiol Rec. 1992;67:11–6.

    Google Scholar 

  21. 21.

    Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis. 2012;16(2):e82–8. https://doi.org/10.1016/j.ijid.2011.10.009.

    Article  PubMed  Google Scholar 

  22. 22.

    Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97–107.

    CAS  Article  Google Scholar 

  23. 23.

    Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of hepatitis B virus infection and impact of vaccination on disease. Clin Liver Dis. 2016;20(4):607–28.

    Article  Google Scholar 

  24. 24.

    Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia–Pacific region. J Gastroenterol Hepatol. 2000;15:E3–E6.

    Article  Google Scholar 

  25. 25.

    Basuni AA, Butterworth L, Cooksley G, Locarnini S, Carman WF. Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries. Vaccine. 2004;22:2791–9. https://doi.org/10.1016/j.vaccine.2004.01.046.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Fitzsimons D, François G, Hall A, McMahon B, Meheus A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine. 2005;23:4158–66. https://doi.org/10.1016/j.vaccine.2005.03.017.

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Viviani S, Jack A, Hall AJ, Maine N, Mendy M, et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine. 1999;17:2946–50. https://doi.org/10.1016/S0264-410X(99)00178-4.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Komas NP, Vickos U, Hübschen JM, Béré A, Manirakiza A, et al. Cross-sectional study of hepatitis B virus infection in rural communities, Central African Republic. BMC Infect Dis. 2013;13:286.

    Article  Google Scholar 

  29. 29.

    Lee KM, Kim YS, Ko YY, Yoo BM, Lee KJ, et al. Emergence of vaccine-induced escape mutant of hepatitis B virus with multiple surface gene mutations in a Korean child. J Korean Med Sci. 2001;16(3):359–62. https://doi.org/10.3346/jkms.2001.16.3.359.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Lin YM, Jow GM, Mu SC, Chen BF. Naturally occurring hepatitis B virus B‑cell and T‑cell epitope mutants in hepatitis B vaccinated children. ScientificWorldJournal. 2013;2013:571875. https://doi.org/10.1155/2013/571875.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Kabir A, Alavian SM, Ahanchi N, Malekzadeh R. Combined passive and active immunoprophylaxis for preventing perinatal transmission of the hepatitis B virus in infants born to HBsAg positive mothers in comparison with vaccine alone. Hepatol Res. 2006;36(4):265–71. https://doi.org/10.1016/j.hepres.2006.08.001.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Esteghamati A, Keshtkar AA, Nadjafi L, Gouya MM, Salaramoli M, Roshandel G, et al. Hepatitis B vaccination coverage among Iranian children aged 15–26 months in 2006. East Mediterr Health J. 2011;17(2):93–100.

    CAS  Article  Google Scholar 

  33. 33.

    Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007;16(4):403–6. https://doi.org/10.1111/j.1542-4758.2008.00284.x.

    Article  PubMed  Google Scholar 

  34. 34.

    Alavian SM, Hajariazdeh B, Ahmadzad Asl M, Kabir A, Bagheri Lankarani KB. Hepatitis B virus infection in Iran: a systematic review. Hepat Mon. 2008;8(4):281–94.

    Google Scholar 

  35. 35.

    Li T, Fu Y, Allain J‑P, Li C. Chronic and occult hepatitis B virus infections in the vaccinated Chinese population. Ann Blood. 2017; https://doi.org/10.21037/aob.2017.04.02.

    Article  Google Scholar 

  36. 36.

    Fortuin M, Karthigesu V, Allison L, Howard C, Hoare S, et al. Breakthrough infections and identification of a viral variant in Gambian children immunized with hepatitis B vaccine. J Infect Dis. 1994;169:1374–6.

    CAS  Article  Google Scholar 

  37. 37.

    Paul S, Saxena A, Terrin N, Viveiros K, Balk EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta-analysis. Ann Intern Med. 2016;164:30–40.

    Article  Google Scholar 

  38. 38.

    Yokoyama K, Kumagai H, Takahashi M, Nagashima S, Okamoto H, Yamagata T. Occult hepatitis B virus infection in immunized children born to carrier mothers. Pediatr Int. 2017;59(9):1010–6.

    CAS  Article  Google Scholar 

  39. 39.

    Amponsah-Dacosta E, Lebelo RL, Rakgole JN, Selabe SG, Gededzha MP, et al. Hepatitis B virus infection in postvaccination South Africa: occult HBV infection and circulating surface gene variants. J Clin Virol. 2015;63:12–7. https://doi.org/10.1016/j.jcv.2014.11.032.

    Article  PubMed  Google Scholar 

  40. 40.

    Mu SC, Lin YM, Jow GM, Chen BF. Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan. J Hepatol. 2009;50(2):264–72. https://doi.org/10.1016/j.jhep.2008.09.017.

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination program in Taiwan. Gut. 2004;53(10):1499–503. https://doi.org/10.1136/gut.2003.034223.

    Article  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Hsu HY, Chang MH, Liaw SH, Ni YH, Chen HL. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology. 1999;30(5):1312–7. https://doi.org/10.1002/hep.510300511.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 25-year universal vaccination program. J Hepatol. 2012;57(4):730–5. https://doi.org/10.1016/j.jhep.2012.05.021.

    Article  PubMed  Google Scholar 

  44. 44.

    Darmawan E, Turyadi, El-Khobar KE, Nursanty NK, Thedja MD, Muljono DH. Seroepidemiology and occult hepatitis B virus infection in young adults in Banjarmasin, Indonesia. J Med Virol. 2015;87(2):199–207. https://doi.org/10.1002/jmv.24045.

    CAS  Article  PubMed  Google Scholar 

  45. 45.

    Elrashidy H, El-Didamony G, Elbahrawy A, Hashim A, Alashker A, et al. Absence of occult hepatitis B virus infection in sera of diabetic children and adolescents following hepatitis B vaccination. Hum Vaccin Immunother. 2014;10(8):2336–41. https://doi.org/10.4161/hv.29521.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Lai MW, Lin TY, Tsao KC, Huang CG, Hsiao MJ, et al. Increased seroprevalence of HBV DNA with mutations in the S gene among individuals greater than 18 years old after complete vaccination. Gastroenterology. 2012;143(2):400–7. https://doi.org/10.1053/j.gastro.2012.05.002.

    CAS  Article  PubMed  Google Scholar 

  47. 47.

    Aghasadeghi MR, Velayati AA, Mamishi S, Nabavi M, Aghakhani A, et al. Low prevalence of hepatitis B vaccine escape mutants among individuals born after the initiation of a nationwide vaccination program in Iran. Arch Virol. 2016;161(12):3405–11. https://doi.org/10.1007/s00705-016-3050-1.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are grateful to Pasteur Institute of Iran for financial support of this study.

Funding

This study was financially supported by Pasteur Institute of Iran, Tehran, Iran

Author information

Affiliations

Authors

Corresponding author

Correspondence to Amitis Ramezani.

Ethics declarations

Conflict of interest

M.R. Aghasadeghi, A. Aghakhani, S. Mamishi, F. Bidari-Zerehpoosh, M.-T.H. Ashtiani, S. Sabeti, M. Banifazl, A. Karami, A. Bavand, and A. Ramezani declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Aghasadeghi, M.R., Aghakhani, A., Mamishi, S. et al. No evidence of occult HBV infection in population born after mass vaccination. Wien Med Wochenschr 170, 218–223 (2020). https://doi.org/10.1007/s10354-020-00748-z

Download citation

Keywords

  • Expanded program of immunization
  • Chronic hepatitis B
  • Vaccination
  • Occult HBV
  • Infection